# A Study in Healthy Adult Male Participants to Learn the Way Vericiguat is Absorbed With and Without Food When Taken as a Single Dose in Liquid Form Suitable for Children Compared to a 10 Milligram (mg) Tablet That Releases the Active Substance Immediately

> **NCT05086952** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 36 (actual)

## Conditions studied

- Heart Failure
- Children

## Interventions

- **DRUG:** Vericiguat (BAY1021189) - Intervention A
- **DRUG:** Vericiguat (BAY1021189) - Intervention B
- **DRUG:** Vericiguat (BAY1021189) - Intervention C
- **DRUG:** Vericiguat (Verquvo, BAY1021189) - Intervention D

## Key facts

- **NCT ID:** NCT05086952
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-12
- **Primary completion:** 2021-12-22
- **Final completion:** 2022-02-15
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2023-02-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05086952

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05086952, "A Study in Healthy Adult Male Participants to Learn the Way Vericiguat is Absorbed With and Without Food When Taken as a Single Dose in Liquid Form Suitable for Children Compared to a 10 Milligram (mg) Tablet That Releases the Active Substance Immediately". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05086952. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*